Thor Medical - Småprat '22 (NANOV) 4

[TekBot]

Flagging Thor Medical ASA

I forbindelse med GF i Thor Medical ASA 24.04.25, har Aksjonærgruppen Thor Medical (AG Thor Medical) ved Jon Magne Asmyr, mottatt 89 åpne fullmakter, totalt 13 934 370 aksjer, tilsvarende 4.43 % av totalt utestående aksjer i Thor Medical ASA. I tillegg innehar Jon Magne Asmyr privat 5 000 000 stemmeberettigede aksjer. Jon Magne Asmyr kontrollerer pr 08.04.25, 18 934 370 aksjer, tilsvarende 6,02 % av totalt utestående aksjer i Thor Medical.

AG Thor Medical består av små og store aksjonærer i selskapet, med felles mål om aktivt eierskap for å synliggjøre og forvalte aksjonærverdiene på best mulig måte. Aksjonærgruppen søker størst mulig oppslutning før GF 24.04.2025. Vi ønsker å påvirke styresammensetningen og sikre at aksjonærgruppen blir representert i styret. Vi oppfordrer små og store aksjonærer i Thor Medical til å sende inn åpne fullmakter enten elektronisk eller via fullmaktsskjema til nis@nordea.no.
…

Vis børsmeldingen

AG Thor Medical
Jon Magne Asmyr

Kilde

[hybrid]

https://agilera.no/pharmalogic-inngar-avtale-med-ife-om-a-kjope-majoritetsandel-i-agilera-pharma-for-a-styrke-sin-globale-posisjon-innen-radiofarmasoytiske-terapimedikamenter/

Konkurrent av Thor Medical ble plutselig “mye større”?

[TekBot]

Thor Medical ASA: Notification of trade for close associates of primary insider

9.4.2025 15:19:54 CEST | Thor Medical ASA | Mandatory notification of trade
primary insiders

…

Vis børsmeldingen

Oslo, Norway, 9 April 2025: Scatec Invest IV, a close associate of Thor Medical
board member John Andersen, has resolved a dividend of shares in Thor Medical
ASA to its shareholders, including to close associates of primary insiders CFO
Brede Ellingsæter and board member John Andersen in Thor Medical ASA.

Scatec Invest IV has distributed a total of 2,811,467 shares in Thor Medical ASA
as dividend, based on a share price of NOK 2,25 per share.

As a result of the distribution, primary insiders have increased their
controlled holding of shares in Thor Medical ASA through their close associates.
B good industries AS, a close associate of Thor Medical ASA CFO Brede
Ellingsæter, has received 1,081,346 shares. Scatec Innovation AS, a close
associate of Thor Medical board member John Andersen, has received 417,053
shares.

Following the distribution, CFO Brede Ellingsæter controls 1,481,346 shares and
holds 3,100,000 share options in Thor Medical.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

This information is subject to disclosure requirements pursuant to the EU Market
Abuse Regulation article 5 and the Norwegian Securities Trading Act section
5-12.

Contacts

Gisle Bjørnstad, CFO, Scatec Innovation AS, +47 95142892,
gisle.bjornstad@scatec.no

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

To learn more, visit www.thormedical.no - http://www.thormedical.no -
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18491057/5930/Download%20announce
ment%20as%20PDF.pdf

20250409 - MAR - Primary insider notifications - Scatec Invest IV AS B Good
industries AS and Scatec Innovation AS.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18491057/5929/20250409%20-%20MAR%
20-%20Primary%20insider%20notifications%20-%20Scatec%20Invest%20IV%20AS%20B%20Go
od%20industries%20AS%20and%20Scatec%20Innovation%20AS.pdf

Kilde

[JMA73]

Hybrid da!? Verken IFE eller Pharmalogic er en konkurrent. De produserer IKKE Thorium 228. Begge er etablert til å sette sammen komponenter i medisin og drive forskning.

[Pk2k]

Stemmer det, de produserer radium-223 og isotoper som brukes i medisinsk bilde behandling.

[hybrid]

Tenkte Agilera Pharma AS, ikke Pharmalogic eller IFE.

Kan hende jeg var litt kjapp, men tolket dette som at de leverer rene isotoper til kliniske prosesser (som er i nedfallskjeden til th228) gjennom sine GMP fasiliteter…

[JMA73]

De har erfaring med å sette sammen ovennevnte isotoper sammen med antistoffene som er komponentene i noen medisiner. De produserer den ikke. IFE produserte Lu177 i sin tid for Nordic Nanovector hvis jeg husker riktig. Det er ikke produksjon av Thorium 228. Muligens har de en generator så de kan forske på Pb212. Men Th228 antar jeg de får fra Oakride eller nå Thor Medical.
Hvis Artbio eller Advancell får godkjent medisin, kan Agilera sette sammen komponentene til ferdig medisin. Men ift Pb212 så bruke nok en annen teknologi mtp den korte halveringstiden. Hvordan Pb212 kobles mot antisstoffet der sprøytene settes, er ganske interessant. Vi får nok mye mer info etterhvert. Oncoinvent gjør jo dette selv i kjelleren i Nydalen.

[hybrid]

Godt du er på ballen, måtte bare sjekke

Neida, var nok litt rask på avtrekkeren der ja.

[TekBot]

Flagging Thor Medical ASA 11.04.2025

I forbindelse med GF i Thor Medical ASA 24.04.25, har Aksjonærgruppen Thor Medical (AG Thor Medical) ved Jon Magne Asmyr, mottatt 230 åpne fullmakter, totalt 27 600 798 aksjer, tilsvarende 8.78 % av totalt utestående aksjer i Thor Medical ASA. I tillegg innehar Jon Magne Asmyr privat 5 000 000 stemmeberettigede aksjer. Jon Magne Asmyr kontrollerer pr 08.04.25, 32 600 798 aksjer, tilsvarende 10,37 % av totalt utestående aksjer i Thor Medical.

AG Thor Medical består av små og store aksjonærer i selskapet, med felles mål om aktivt eierskap for å synliggjøre og forvalte aksjonærverdiene på best mulig måte. Aksjonærgruppen søker størst mulig oppslutning før GF 24.04.2025. Vi ønsker å påvirke styresammensetningen og sikre at aksjonærgruppen blir representert i styret. Vi oppfordrer små og store aksjonærer i Thor Medical til å sende inn åpne fullmakter enten elektronisk eller via fullmaktsskjema til nis@nordea.no.
…

Vis børsmeldingen

AG Thor Medical
Jon Magne Asmyr

Kilde

[TekBot]

Flagging Thor Medical ASA 11 April 2025

11.4.2025 18:27:35 CEST | Thor Medical ASA | Major shareholding notifications

Oslo, 11 April 2025
…

Vis børsmeldingen

Ludvik Sandnes, Chairman of the Board at Thor Medical ASA (the “Company”), has
received proxies without voting instructions to vote for a total of 15,786,906
shares at the Company’s Annual General Meeting on 24 April 2025, representing
approx. 5.00 percent of all shares in the Company. Additionally, Sandnes has
received proxies with voting instructions to vote for a total of 3,046,978
shares at the Company’s Annual General Meeting on 24 April 2025, representing
approx. 0.97 percent of all shares in the Company.

Furthermore, Sandnes owns 626,489 shares, representing approx. 0.20 percent of
all shares issued in the Company, as well as 300,000 shares, representing
approx. 0.10 percent of all issued shares in the Company through Ekornhuset AS.
Sandnes will be able to cast votes at the Annual General Meeting for a total of
19,760,375 shares, representing approx. 6.27 percent of all issued shares in the
Company.

The received proxies are valid only for the aforementioned General Meeting and
will automatically expire, so that after the General Meeting, Sandnes will own
926,489 shares in the Company, including the shares owned by Ekornhuset AS.

This notification is issued because Sandnes has been granted proxies without
voting instructions for more than 5% of all voting rights in the Company. The
notification does not indicate that the aforementioned is the final number of
shares Sandnes will be able to vote for at the Annual General Meeting.

This information is subject to disclosure requirements pursuant to Section 4-2
of the Securities Trading Act.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18495673/5936/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Thor Medical ASA: Completion of annual general meeting

24.4.2025 15:03:03 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

…

Vis børsmeldingen

Oslo, Norway, 24 April 2025

The annual general meeting in Thor Medical ASA (the “Company”) was held today,
24 April 2025. All items on the agenda were approved in accordance with the
notice. The minutes are attached hereto and are also available on
https://www.thormedical.no/.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’. To learn
more, visit www.thormedical.no - http://www.thormedical.no

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18503732/5972/Download%20announce
ment%20as%20PDF.pdf

Thor Medical ASA - Minutes from ordinary general meeting 24 April 2.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18503732/5971/Thor%20Medical%20AS
A%20-%20Minutes%20from%20ordinary%20general%20meeting%2024%20April%202.pdf

Kilde

[TekBot]

Thor Medical - Grant of restricted stock units (RSU) to the members of the board

2.5.2025 19:55:48 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

…

Vis børsmeldingen

Oslo, Norway, 2 May 2025

Reference is made to the stock exchange announcement made by Thor Medical ASA
(the “Company”) the Company on 24 April 2025 whereby it was disclosed that the
Company’s annual meeting resolved (“AGM”), among other things, the approval of a
restricted share units (“RSU”) program.

At the AGM, the shareholders approved the remuneration to the Company’s current
board of directors whereby the board members were given the choice to receive
their remuneration, or a part thereof, for the period from the AGM to the annual
general meeting of 2026, in the form of restricted share units (“RSU”), as a
part of the Company’s RSU program. The allocation of RSUs has today been made.

The number of RSUs allocated to each board member has been determined based on
the NOK value for the RSU-selected portion of the total compensation for the
board member. The compensation is divided by the subscription price of NOK
2.4295, equal to the 10-day volume weighted average prior the general meeting. A
total of 274,401 RSUs has been allocated to the following board members:

• Mimi Kristine Berdal: 54,880 RSUs
• Thomas Ramdahl: 54,880 RSUs
• Jens Gisle Schnelle: 164,641 RSUs

Primary insider notifications pursuant to the market abuse regulation article 19
are attached. This information is required to be disclosed under Section 5-12 of
the Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

To learn more, visitwww.thormedical.no - http://visitwww.thormedical.no -
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514604/6040/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Thor Medical - Primary insider notifications - Grant of restricted stock units (RSU) to the members of the board

2.5.2025 23:06:46 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

…

Vis børsmeldingen

Oslo, Norway, 2 May 2025

Reference is made to the stock exchange announcement made by Thor Medical ASA
(the “Company”) the Company on 2 May 2025 regarding the grant of restricted
share units (“RSU”) to members of the board of directors.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached hereto. This information is required to be disclosed under Section
5-12 of the Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

To learn more, visitwww.thormedical.no - http://visitwww.thormedical.no -
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514642/6044/Download%20announce
ment%20as%20PDF.pdf

Jens Gisle Schnelle - Primary insider notifications.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514642/6041/Jens%20Gisle%20Schn
elle%20-%20Primary%20insider%20notifications.pdf

Mimi K Berdal - Primary insider notifications.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514642/6042/Mimi%20K%20Berdal%2
0-%20Primary%20insider%20notifications.pdf

Thomas Ramdahl - Primary insider notifications.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514642/6043/Thomas%20Ramdahl%20
-%20Primary%20insider%20notifications.pdf

Kilde

[Georg]

Oslo (Infront TDN Direkt): Arctic Securities tar opp dekning på Thor Medical med kjøpsanbefaling og et kursmål på 4,0 kroner pr aksje.

[JMA73]

Dette innlegget ble rapportert og er midlertidig skjult.

[Pk2k]

@JMA73

we believe the undisclosed strategic partner is Bayer, a global leader in radiopharmaceuticals.

Den setningen der

[Oilimp]

Sliter med å skjønne hvorfor dette innlegget er skjult? @pdx ?

[pdx]

I analysen står det: “It may not be reproduced, redistributed or republished by any recipient for any purpose or to any person. If you are not a client of Arctic, you are not entitled to receive the report.”

[Savepig]

Bedre å gjengi slike pressemeldinger:

THOR MEDICAL: ARCTIC TAR OPP DEKNING MED KJØP, KURSMÅL 4,0

i dag kl. 08:13 ∙ TDN Finans

Oslo (Infront TDN Direkt): Arctic Securities tar opp dekning på Thor Medical med kjøpsanbefaling og et kursmål på 4,0 kroner pr aksje.

Det fremgår av en analyse fra meglerhuset mandag.

Arctic mener markedet undervurderer Thor Medicals potensial, ettersom dagens aksjekurs innebærer begrenset tro på selskapets kommersielle suksess.

“Vi ser flere triggere for aksjen fremover, inkludert ekspansjonsplaner for AlphaOne, som indikerer at etterspørselen allerede overstiger forventet kapasitet”, skriver meglerhuset.

---

Jeg mener som vanlig at slike analyser ikke engang kan brukes til å tørke seg bak med, og ikke bare fordi det kun foreligger digital.

[Investor]

@Georg

Oslo (Infront TDN Direkt): Arctic Securities tar opp dekning på Thor Medical med kjøpsanbefaling og et kursmål på 4,0 kroner pr aksje.

Trodde AS hadde sluttet med dekning på helsekasjer for en god stund siden. Kan dette bety at en emi er nært forestående.